26th May 2022 15:00
26 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by a show of hands.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website, www.diaceutics.com.
Resolution | For (excluding at Chair's discretion) | Against | Total votes cast | Withheld | |||
|
| Number of votes | % | Number of votes | % |
| Number of votes |
1 | Ordinary resolution to receive and consider the 2021 Financial Statements | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 |
Nil
|
2 | Ordinary resolution to approve the directors' remuneration report | 62,693,325 | 99.99% | 7,350 | 0.01% | 62,700,675 | Nil |
3 | Ordinary resolution to re-elect Nick Roberts as a director | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 | Nil |
4 | Ordinary resolution to re-elect Charles Hindson as a director | 61,651,904 | 98.32% | 900,000 | 1.44% | 62,551,904 | Nil |
5 | Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors | 62,550,243 | 99.75% | 1,661 | 0.01% | 62,551,904 | Nil |
6 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors | 62,700,675 | 100.00% | 0 | 0.00% | 62,700,675 |
Nil
|
7 | Ordinary resolution to authorise the directors to allot shares | 62,699,175 | 100.00% | 0 | 0.00% | 62,700,675 |
1,500
|
8 | Special resolution to authorise the directors to disapply pre-emption rights | 62,697,164 | 99.9% | 2,011 | 0.01% | 62,699,175 |
1,500 |
9 | Special resolution to authorise the directors to purchase own shares | 60,606,084 | 99.99% | 8,661 | 0.01% | 62,614,745 |
2,085,930 |
Enquiries:
Diaceutics PLC | |
Peter Keeling, Chief Executive Officer | Via Alma PR |
Nick Roberts, Chief Financial Officer | |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison, Stewart Wallace, Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde, Kieran Breheny, Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Related Shares:
Diaceutics